BioLineRx (BLRX) Short term Debt (2015 - 2025)

BioLineRx's Short term Debt history runs 11 years deep, the most recent figure standing at $4.5 million for Q4 2025.

• On a quarterly basis, Short term Debt changed 0.0% year-over-year to $4.5 million in Q4 2025; TTM through Dec 2025 was $4.5 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $4.5 million, changed 0.0% from the prior year.
• Short term Debt held at $4.5 million in Q4 2025 per BLRX's latest filing, from $4.5 million in the prior quarter.
• Across five years, Short term Debt topped out at $10.7 million in Q2 2024 and bottomed at $802000.0 in Q3 2022.
• The 5-year median for Short term Debt is $3.3 million (2021), against an average of $3.8 million.
• Across the five-year window, Short term Debt sank 77.57% in 2022 and jumped 283.79% in 2023, its largest moves.
• Year by year, Short term Debt stood at $2.8 million in 2021, then sank by 44.07% to $1.5 million in 2022, then soared by 103.96% to $3.1 million in 2023, then surged by 42.42% to $4.5 million in 2024, then changed by 0.0% to $4.5 million in 2025.
• Per Business Quant, the three latest BLRX Short term Debt figures stand at $4.5 million (Q4 2025), $4.5 million (Q3 2025), and $4.5 million (Q2 2025).